Hostname: page-component-7c8c6479df-p566r Total loading time: 0 Render date: 2024-03-29T04:48:11.534Z Has data issue: false hasContentIssue false

Efficacy of vortioxetine for patients with dual pathology

Published online by Cambridge University Press:  23 March 2020

E. Barbero García
Affiliation:
CAID Majadahonda, Drug Addiction Attention Center, Majadahonda, Madrid, Spain
D. Baño Rodrigo
Affiliation:
CAID Majadahonda, Drug Addiction Attention Center, Majadahonda, Madrid, Spain
M. Agujetas Rodríguez
Affiliation:
CAID Majadahonda, Drug Addiction Attention Center, Majadahonda, Madrid, Spain
A. García Sanchez
Affiliation:
CAID Majadahonda, Drug Addiction Attention Center, Majadahonda, Madrid, Spain
V. De Antonio Pérez
Affiliation:
CAID Majadahonda, Drug Addiction Attention Center, Majadahonda, Madrid, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Patients with dual pathology have worse clinical evolution and worse therapeutic response. Drugs modify the functioning of certain neurocerebral transmission systems, producing cognitive, emotional and behavioral changes. Vortioxetine (Brintellix®) is used as a treatment for major depressive disorder (MDD) and it is considered a new multimodal antidepressant. Preclinical data suggest that the effects on numerous serotonin receptors result in regional increases in noradrenaline and dopamine as well as glutamatergic transmission.

Objectives

This analysis assessed the efficacy of vortioxetine (Brintellix®) in patients with affective disorders and abuse drugs (dual pathology).

Methods

Efficacy was assessed with a study of patients who were recruited in a qualitative and observational study. They were treated with vortioxetine (Brintellix®). Outcome measures included changes from baseline to endpoint in Hamilton Depresion Rating Scale (HDRS). They were also interviewed weekly about craving and substance use. Urine test controls were done to corroborate results.

Results

A total of 11 vortioxetine-treated patients improved their depressive and anxiety symptomatology. Seven of them (64%) were males and four of them (36%) were women. Cocaine was the main drug of abuse (n = 9, 82%). The doses were between 5 and 20 mg/day. After the clinical evaluation and 12 weeks of treatment, they achieved to reduce significantly the drug use and verbalized a decrease in craving. Two patients dropped out of the study.

Conclusions

Vortioxetine (Brintellix®) was shown as efficacious in reducing depressive and anxiety symptoms in patients with dual pathology.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster viewing: Substance related and addictive disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.